ArticleDiscover oncology2025
ANAPC10 expression predicts poor prognosis in oral squamous cell carcinoma and promotes tumor growth via the PI3K/AKT/mTOR pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MCVAE-based multi-omic anomaly detection in Fragile X Syndrome.NAR molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is associated with high morbidity and mortality, emphasizing the need for early detection through advanced biomarkers and non-invasive methods. This study analyzed Anaphase Promoting Complex Subunit 10 (ANAPC10) mRNA expression across various cancers using multi-platform tools to assess its diagnostic potential and clinical relevance. We developed a prognostic model linking ANAPC10 expression to survival outcomes using TCGA and GTEx data, and constructed a protein-protein interaction network via GeneMANIA. Functional studies, including cell culture and various assays, demonstrated that ANAPC10 is highly expressed in OSCC and correlates with poor prognosis. ANAPC10 was found to be involved in key pathways, including NF-κB signaling and cell cycle regulation. Knockdown experiments revealed that reducing ANAPC10 expression led to decreased cell proliferation, migration, and invasion, as well as inhibition of the PI3K/AKT/mTOR signaling pathway. These findings suggest that ANAPC10 is a promising biomarker for OSCC and a potential therapeutic targetClinical Trial Number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.